New FDA Approval for the Rare Blood Cancer BPDCN: CD123-Targeted Pivekimab Sunirine
In this article
FDA Approves Pivekimab Sunirine for the Rare and Aggressive Blood Cancer BPDCN: A New CD123-Targeted Antibody-Drug Conjugate
BPDCN: A Rare, Aggressive Hematological Cancer Whose Diagnosis Can Easily Be Missed
BPDCN is a very rare hematological malignancy originating from plasmacytoid dendritic cells. Clinically, it often begins with purple-brown, bruise-like or nodular skin lesions; however, the disease can rapidly spread to the bone marrow, peripheral blood, lymph nodes and sometimes the central nervous system. It is therefore a distinctive disease requiring dermatology, hematology and pathology to work together, and its diagnosis can be delayed.
One of the disease's most prominent biological features is that, in tumor cells, CD123 is strongly expressed. CD123 is the interleukin-3 receptor alpha chain and is highly important in BPDCN both for diagnosis and as a therapeutic target. For this reason, the most important developments in BPDCN treatment in recent years have centered on CD123-targeted agents.
Brief Concept Note: What Do BPDCN and CD123 Mean?
BPDCNstands for “blastic plasmacytoid dendritic cell neoplasm”; in Turkish it is called “blastik plazmasitoid dendritik hücre neoplazisi.” The word “blastic” refers to immature, rapidly proliferating cells. CD123 is a protein found at high levels on the surface of these cancer cells and acts as a biological address that enables the drug to recognize the cancer cell.
Historically, BPDCN has had a poor prognosis. Although conventional intensive chemotherapy can produce an initial response, relapse is common. In eligible patients who respond, allogeneic hematopoietic stem cell transplantation is considered an important strategy for long-term disease control. However, because BPDCN mostly occurs at an older age, not every patient is eligible for intensive chemotherapy or transplantation.
How Does Pivekimab Sunirine Work?
Pivekimab sunirine, as an antibody-drug conjugate , is designed with an antibody component that binds to CD123; when the drug payload is carried into the cell, it aims to kill the tumor cell by causing DNA damage. Unlike the more widespread effects of chemotherapy throughout the body, this approach aims to deliver the cytotoxic payload more selectively to CD123-positive cells.
The FDA text describes pivekimab sunirine as a conjugate of a CD123-targeted antibody and an alkylating agent. The term “alkylating” refers to a class of drugs that stop cell division by damaging DNA.
Which Patients Does the Approval Cover?
With a diagnosis of BPDCN, adult patients are covered by the FDA approval. The CADENZA study included both newly diagnosed patients who had not previously received systemic treatment and patients with relapsed or refractory BPDCN. Patients with active central nervous system disease were not enrolled in the study.
Treatment-naive
Refers to newly diagnosed adult patients who have not previously received systemic treatment for BPDCN.
Relapse
The recurrence of the disease after it responded to previous treatment.
Refractory
The disease does not respond adequately to the treatment given or follows a resistant course.
How Was the CADENZA Study Designed?
The CADENZA study, which formed the basis of the FDA approval, was a multicenter, open-label, single-arm clinical study. A total of 84 adult patients with BPDCN were evaluated: 33 were treatment-naive, while 51 were in the relapsed or refractory disease group. The efficacy measure, complete remission or clinical complete remission, was expressed as a rate.
Brief Concept Note: What Do CR and CRc Mean?
CRmeans complete remission; it refers to the disease becoming undetectable on standard assessments. CRc means clinical complete remission; particularly in diseases with prominent skin involvement, such as BPDCN, it can describe a state very close to a complete response, along with certain clinical details such as minimal skin findings. The main response measure in the FDA approval is the composite CR/CRc rate.
| Patient group | Number of patients | Follow-up duration | CR/CRc rate | Median response duration | Clinical significance |
|---|---|---|---|---|---|
| Treatment-naive BPDCN | 33 | Median 21,5 months | 23/33 patients; 69,7% 95% CI: 51,3%–84,4% |
9,7 months 95% CI: 2,9 months - not estimable |
A strong signal for the potential to produce deep responses and serve as a bridge to transplantation in newly diagnosed patients. |
| Relapsed/refractory BPDCN | 51 | Median 24,1 months | 8/51 patients; 15,7% 95% CI: 7,0%–28,6% |
9,2 months Range: 2,7-27,6+ months |
Limited but clinically meaningful response activity in the previously treated, resistant patient group. |
Approximately 70% Complete/Clinical Complete Response in Newly Diagnosed Patients
The strongest efficacy signal in the CADENZA study was seen in newly diagnosed patients. CR/CRc was achieved in 23 of 33 treatment-naive patients. This corresponds to approximately %70 for the response rate. This rate is important in a disease such as BPDCN, which is rare, aggressive and has historically had limited treatment options.
Clinical Significance of This Result
- Strong response at new diagnosis: The CR/CRc rate of 69,7% shows that pivekimab sunirine can produce deep responses in treatment-naive BPDCN.
- More limited effects in relapsed/refractory disease: In previously treated patients, CR/CRc remained at 15,7%; this group may be biologically more resistant.
- Similar response duration: Among patients who responded, the median CR/CRc duration was around 9,7 months at new diagnosis and 9,2 months in the relapsed/refractory group.
- Bridging strategy: For eligible patients who achieve a deep response, proceeding to allogeneic stem cell transplantation may be an important clinical goal.
A Bridge to Transplantation: Why Does Response Depth Matter in BPDCN?
Allogeneic hematopoietic stem cell transplantation is an important strategy for long-term disease control in BPDCN. However, transplantation can often be performed only in patients with an adequate response, suitable performance status and manageable comorbidities. The purpose of initial treatment in newly diagnosed BPDCN is therefore not merely temporary tumor shrinkage; if possible, it is to produce a deep remission and safely take the patient to transplantation.
According to AbbVie's announcement, 39,4% of newly diagnosed patients and 11,8% of relapsed/refractory patients in CADENZA were able to receive stem cell transplantation after the study. These data suggest that pivekimab sunirine may have a role as a “bridging treatment,” particularly in newly diagnosed patients.
The Second CD123 Era After Tagraxofusp
The targeted treatment revolution in BPDCN began with the approval of tagraxofusp-erzs in 2018. Tagraxofusp is an interleukin-3-based fusion toxin that binds to CD123 and is the first drug to receive FDA approval for BPDCN. Before this approval, treatment relied mainly on intensive chemotherapy regimens similar to those used for acute leukemia or lymphoma; however, responses to these approaches were often not durable, and toxicity created significant problems in older patients.
Pivekimab sunirine represents a second important step in this historical trajectory. Although both agents target CD123, their structures differ: tagraxofusp is a CD123-targeted cytotoxic fusion protein, while pivekimab sunirine is a CD123-targeted antibody-drug conjugate. This difference is important for the mechanism of action, method of administration, toxicity profile and combination potential.
| Treatment | Year of FDA approval | Target / structure | Approved population | Key efficacy data | Notable safety issue |
|---|---|---|---|---|---|
| Tagraxofusp-erzs | 2018 | CD123-targeted IL-3/diphtheria toxin fusion protein | BPDCN; adults and pediatric patients over 2 years of age | CR/CRc of 53,8% in the pivotal treatment-naive cohort; 2 CR/CRc among 15 patients in the relapsed/refractory group | Capillary leak syndrome, hypoalbuminemia, edema, hypotension and changes in liver enzymes |
| Pivekimab sunirine-pvzy | 2026 | Conjugate of a CD123-targeted antibody and an alkylating agent | Adult BPDCN | In CADENZA, CR/CRc of 69,7% at new diagnosis and 15,7% in relapsed/refractory disease | Boxed warning for hepatotoxicity and hepatic veno-occlusive disease; infusion reaction, edema, sulfite allergy |
Truecheck Note: This Table Is Not a Direct Head-to-Head Comparison
Tagraxofusp and pivekimab sunirine were evaluated in different years, with different patient numbers and different study designs. It is therefore incorrect to interpret the response rates directly as “which is better?” However, viewing them side by side is clinically informative for understanding how CD123-targeted treatments have evolved historically in BPDCN.
From Conventional Chemotherapy to Targeted Bridging Treatments
Historically, attempts to treat BPDCN have used chemotherapy regimens resembling those for AML, ALL/lymphoblastic lymphoma or CHOP. Although these regimens can produce initial responses, the disease often relapses rapidly. In eligible patients, transplantation is a critical step for long-term control; however, a deep response is needed first in order to reach transplantation.
The value of CD123-targeted treatments becomes apparent precisely here. Tagraxofusp changed the field as the first approved targeted agent for BPDCN. Pivekimab sunirine uses the same target through a different technology, with its antibody-drug conjugate architecture. This suggests that BPDCN treatment may evolve in the future from single-agent treatment toward much more refined strategies, such as bridging before transplantation, an approach guided by minimal residual disease monitoring or combination treatments.
| Approach | Patient context | Advantage | Limitation | Current clinical significance |
|---|---|---|---|---|
| Intensive chemotherapy | Young/fit patients; regimens resembling those for AML/ALL/lymphoma | Can provide rapid cytoreduction and an initial response | Frequent relapse; high toxicity at an older age; no BPDCN-specific targeting | Can still be used in selected patients; however, targeted agents have changed the field. |
| Allogeneic stem cell transplantation | Patients who have achieved a deep response and have suitable performance status and organ function | Long-term disease control and a potential chance of cure | Limited by age, comorbidity, donor suitability and transplant toxicity | Remains an important goal for eligible patients after a deep response at new diagnosis. |
| Tagraxofusp | BPDCN; adult and pediatric patients | First approved CD123-targeted treatment; began the targeted treatment era in BPDCN | Capillary leak syndrome and the need for close monitoring | A historical milestone demonstrating the clinical value of targeting CD123. |
| Pivekimab sunirine | Adult BPDCN; activity in newly diagnosed and relapsed/refractory groups | CD123-targeted ADC; IV administration every 3 weeks; high CR/CRc rate at new diagnosis | Boxed warning for hepatotoxicity/VOD; more limited CR/CRc in the relapsed/refractory group | A new option for a deep response at new diagnosis and a strategy of bridging to transplantation. |
Boxed Warning: Hepatotoxicity and Veno-Occlusive Disease
The prescribing information for pivekimab sunirine identifies hepatotoxicity, meaning liver damage, and hepatic veno-occlusive disease as conditions covered by a boxed warning. Veno-occlusive disease is a serious condition involving blockage of the liver's small vessels and impaired liver function; it requires close monitoring, particularly during treatment of hematological malignancies and in the transplantation setting.
Safety Note
- Liver monitoring: Liver function tests should be carefully monitored before and during treatment.
- Veno-occlusive disease: Attention should be paid to rapid weight gain, right upper quadrant pain, increased bilirubin, fluid in the abdomen and enlargement of the liver.
- Infusion reactions: Reactions such as fever, chills, shortness of breath, hypotension or rash should be monitored.
- Edema: Peripheral edema and fluid overload may be clinically important, particularly in frail patients.
- Sulfite allergy: The prescribing information includes a warning for allergic reactions to sulfites.
The Toxicity Difference From Tagraxofusp: Capillary Leak Versus a Liver Warning
The toxicity profile of CD123-targeted treatments directly affects treatment selection. Historically, capillary leak syndrome has been the toxicity receiving the most attention with tagraxofusp. For pivekimab sunirine, the FDA boxed warning focuses on hepatotoxicity and hepatic veno-occlusive disease. Therefore, although both agents address the same target, their monitoring algorithms differ.
Brief Concept Note: Capillary Leak and Veno-Occlusive Disease
Capillary leak syndromeis the development of edema, low blood pressure, weight gain and low albumin as fluid leaks from blood vessels into tissues. Hepatic veno-occlusive disease is the impairment of liver function resulting from damage and blockage in the liver's small vessels. Both conditions can be severe if they are not recognized early.
The Greatest Value in Newly Diagnosed Patients: A Deep Response and Reaching Transplantation
In the CADENZA data, the greatest strength of pivekimab sunirine is its high CR/CRc rate in newly diagnosed patients. This rate suggests that, within a treatment strategy, the drug can be considered not only for temporary disease control but also for a deep response and as a bridge to transplantation.
The CR/CRc rate remaining at 15,7% in the relapsed/refractory group shows that the treatment has more limited but still meaningful activity in this patient group. Considering the restricted options after relapse in BPDCN, even deep responses occurring at a low rate may be clinically valuable, particularly if they open the door to transplantation or a clinical study for a responding patient.
How Should This Be Discussed With a Patient?
“BPDCN is a very rare blood cancer that can progress rapidly. Newly approved pivekimab sunirine is a smart treatment that recognizes the target called CD123 on the cancer cell's surface and delivers an effective drug into the cell. In newly diagnosed patients, a complete or near-complete response has been reported in approximately 7 of 10 patients. However, close monitoring is needed because the treatment can carry serious liver-related side effects.”
Practical Clinical Questions
- Is the diagnosis certain? The diagnosis of BPDCN should be confirmed through expert hematopathology, immunohistochemistry and markers such as CD123/CD4/CD56/TCL1.
- Has the central nervous system been assessed? CNS involvement is clinically important in BPDCN; CADENZA included patients without active CNS disease.
- Is the patient a candidate for transplantation? An allogeneic transplantation strategy should be considered early after a deep response at new diagnosis.
- Is there a liver risk? Liver function, hepatitis status, previous hepatotoxicity and the transplant plan should be assessed before treatment.
- Is MRD monitoring possible? In the future, minimal residual disease monitoring may allow more informed decisions about treatment duration and transplantation.
CD123-Targeted Treatments Continue to Change the Course of BPDCN
This FDA approval is important because it brings a new CD123-targeted antibody-drug conjugate into the treatment landscape for the very rare and aggressive disease blastic plasmacytoid dendritic cell neoplasm.
Its clinical value lies in providing a meaningful option for strategies aimed at bridging treatment or deep response, particularly with a complete response rate approaching 70% in newly diagnosed patients.
In the future, the patients who will derive the most durable benefit from this drug together with transplantation, combination treatments and MRD monitoring should be defined more clearly.
The Next Question in BPDCN: A Single Agent, Combination or Integration With Transplantation?
The approval of pivekimab sunirine expands the treatment landscape in BPDCN; however, it does not resolve every question. The most critical question is how this agent will be positioned alongside tagraxofusp, venetoclax-based combinations, hypomethylating agents, intensive chemotherapy or transplantation strategies.
The high CR/CRc rate in newly diagnosed patients makes pivekimab sunirine attractive as a bridging treatment to transplantation. The lower but meaningful response rate in patients with relapsed/refractory disease is valuable, particularly for those with limited other options. However, more data are needed on long-term survival, MRD negativity, outcomes after transplantation and combination treatments.
A Balanced Interpretation for Today
This approval provides a new and important option in BPDCN; however, it does not show that pivekimab sunirine is directly superior to tagraxofusp or intensive chemotherapy. CADENZA is a single-arm study. The most appropriate clinical approach is therefore multidisciplinary decision-making that considers the patient's age, performance status, organ function, CNS involvement, transplant eligibility and previous treatments.
A New FDA Approval in BPDCN: A Meaningful Step Forward in a Rare Disease
The FDA approval of pivekimab sunirine-pvzy is an important development in an ultra-rare and aggressive hematological malignancy such as BPDCN. The CADENZA study reported a CR/CRc rate of 69,7% in newly diagnosed adult patients and 15,7% in patients with relapsed/refractory disease. A response duration of approximately 9 months creates a clinical window that may serve as a bridge, particularly to transplantation or subsequent treatment strategies.
The historical value of this approval is that it represents the second strong technological wave of CD123 targeting in BPDCN treatment. Tagraxofusp began the CD123-targeted treatment era; pivekimab sunirine provides a new option by using the same target through an antibody-drug conjugate architecture.
Nevertheless, safety must be managed carefully. The boxed warning for hepatotoxicity and hepatic veno-occlusive disease indicates that this treatment should be administered in experienced centers, with attention to liver function and the transplantation plan. The future of BPDCN is moving beyond a single drug toward a more personalized treatment era in which CD123 targeting, transplantation, MRD monitoring and smart combinations are planned together.
References
- U.S. FDA. FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy. 27 May 2026.
- AbbVie. U.S. FDA Approves DECNUPAZ™ (pivekimab sunirine-pvzy) for Treatment of Adult Patients With BPDCN. 27 May 2026.
- ClinicalTrials.gov. CADENZA study: pivekimab sunirine in CD123-positive hematologic malignancies including BPDCN. NCT03386513.
- The ASCO Post. High Response Rates With Front-Line Pivekimab Sunirine in BPDCN. 19 February 2026.
- Pemmaraju N et al. Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm. Journal of Clinical Oncology. 2026.
- U.S. FDA. FDA approves tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm. 26 December 2018.
- Jen EY et al. FDA Approval Summary: Tagraxofusp-erzs for Treatment of BPDCN. Clinical Cancer Research. 2020.
- The ASCO Post. Overcoming BPDCN: Tagraxofusp Sets New Landmark in Patient Survival. 20 December 2023.
- Luskin MR et al. Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm. Haematologica. 2024.
- StatPearls / NCBI Bookshelf. Blastic Plasmacytoid Dendritic Cell Neoplasm. Updated 2024.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.